Inclusion Criteria:

          1. ALL:ALL high risk including one or more of the following: (t(9;22) or 11q23
             chromosomal abnormality, primary induction failure (<15% blasts at time of
             registration), mixed phenotype acute leukemia (MPAL), persistent MRD (<0.01% by flow
             or persistent abnormal karyotype detected by cytogenetics) or hypodiploidy (44
             chromosomes)) in first remission ' ALL in second remission and beyond;

          2. AML: History of AML induction/reinduction Failure (<15% blasts at time of
             registration); AML in CR1 with poor cytogenetics (i.e. 12p, 5a, -7, FLT3
             mutation/duplication, t(9;11) and others); AML with persistent minimal residual
             disease (MRD) in CR1(<0.01% on flow or persistent abnormal karyotype detected by
             cytogenetics); AML CR2 or beyond; AML in refractory relapse but ≤15% bone marrow
             leukemia blasts; Therapy-related AML

          3. High Risk Myelodysplastic syndrome (MDS) 4 Lymphoma: Hodgkin (HL) or Non-Hodgkin
             (NHL): HL or NHL in induction failure; HL or NHL in PR1 or PR2 ; HL or NHL in CR2 or
             subsequent remission

        5. Bone marrow failure syndromes: Kostmann syndrome refractory or intolerant to granulocyte
        colony-33stimulating factor; Diamond-Blackfan anemia refractory or intolerant to
        corticosteroids and/or cyclosporine'; amegakaryocytic thrombocytopenia 6. Sickle Cell
        Disease (Homozygous Hemoglobin S Disease, or Hemoglobin S β 0/+ thalassemia, or Hemoglobin
        SC Disease) 7. age 0-30 years 8. adequate organ function

        Exclusion Criteria:

          1. Females who are pregnant or breast-feeding are not eligible.

          2. Patients with documented uncontrolled infection at the time of study entry are not
             eligible.

          3. Karnofsky/Lansky (age appropriate) Performance Score <60

          4. Demonstrated lack of compliance with medical care

          5. Patients who have received allogeneic HSCT within 6 months, unless being done as a
             boost.

          6. Patients with active <Grade 2 GVHD.